Cytokine Regulation in Alzheimer’s Disease

  • Robert E. Mrak
Part of the Neurobiological Foundation of Aberrant Behaviors book series (NFAB, volume 7)

Abstract

The idea that Alzheimer’s disease involves an ‘inflammation-like’ process, involving orchestrated cytokine and cellular responses that culminate in neuronal injury and destruction, has become so widely accepted that it is now difficult to remember how radical this idea was less than a decade ago. Alzheimer’s disease, at that time, was seen as a ‘neurodegenerative’ disease, in which accumulations of Aβ protein damaged neurons through direct and, we thought, soon-to-be elucidated, toxic mechanisms. Any associated glial cells were considered to be passive or ‘reactive’ late-comers, of no significance toward understanding the disease or its progression.

Keywords

Migration Toxicity Ischemia Dementia Cysteine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Griffin, W.S.T., Stanley, L.C., Ling, C., et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86: 7611–7615.PubMedGoogle Scholar
  2. 2.
    Bauer, J., Strauss, S., Schreiter-Gasser, U., et al. Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices. FEBS Lett 1991; 285:111–4.PubMedGoogle Scholar
  3. 3.
    van der Wal, E.A., Gomez-Pinilla, F., Cotman, C.W. Transforming growth factor-β1 is in plaques in Alzheimer and Down pathologies. Neuroreport 1993; 4: 69–72.PubMedGoogle Scholar
  4. 4.
    Akiyama, H., Ikeda, K., Katoh, M., et al. Expression of MRP14, 27E10, interferon-α and leukocyte common antigen by reactive microglia in postmortem human brain tissue. J Neuroimmunol 1994; 50: 195–201.PubMedGoogle Scholar
  5. 5.
    Yamada T., Horisberger, M.A., Kawaguchi, et al. Immunohistochemistry using antibodies to α -interferon and its induced protein, MxA, in Alzheimer’s and Parkinson’s disease brain tissues, Neurosci Lett 1994; 181: 61–4.PubMedGoogle Scholar
  6. 6.
    Araujo, D.M., Lapchak, P.A. Induction of immune system mediators in the hippocampal formation in Alzheimer’s and Parkinson’s diseases: selective effects on specific interleukins and interleukin receptors. Neuroscience 1994; 61:745–54.PubMedGoogle Scholar
  7. 7.
    Wisniewski, T., Lalowski, M, Baumann, M., et al. HB-GAM is a cytokine present in Alzheimer’s and Down’s syndrome lesions. Neuroreport 1996; 7: 667–71.PubMedGoogle Scholar
  8. 8.
    Wallace, M.N., Geddes, J.G., Farquhar, D.A., et al. Nitric oxide synthase in reactive astrocytes adjacent to β-amyloid plaques. Exp Neurol 1997; 144: 266–72.PubMedGoogle Scholar
  9. 9.
    Du Yan, S., Zhu, H., Fu, J., et al. Amyloid-β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a pro-inflamatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A 1997; 94: 5296–301.PubMedGoogle Scholar
  10. 10.
    Xia, M., Qin, S., McNamara, M, et al. Interleukin-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer’s disease. Am J Pathol 1997; 150: 1267–74.PubMedGoogle Scholar
  11. 11.
    Ishizuka, K., Kimura, T., Igata-yi, R., et al. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer’s disease. Psychiatry. Clin Neurosci 1997; 51: 135–8.PubMedGoogle Scholar
  12. 12.
    Xia, M.Q., Qin, S.X., Wu, L.J., et al. Immunohistochemical study of the β-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer’s disease brains. Am J Pathol 1998; 153: 31–7.PubMedGoogle Scholar
  13. 13.
    Nakamura, S., Arima, K., Haga, S., et al. Fibroblast growth factor (FGF)-9 immunoreactivity in senile plaques. Brain Res 1998; 814: 222–5.PubMedGoogle Scholar
  14. 14.
    Kalaria, R.N., Cohen, D.L., Premkumar, D.R., et al. Vascular endothelial growth factor in Alzheimer’s disease and experimental cerebral ischemia. Brain Res Molec Brain Res 1998; 62: 101–5.Google Scholar
  15. 15.
    Xia, M.Q., Bacskai, B.J., Knowles, R.B., et al. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer’s disease. J Neuroimmunol 2000; 108: 227–35.PubMedGoogle Scholar
  16. 16.
    Barger, S.W., Mattson, M.P. Secreted form of the Alzheimer’s amyloid precursor protein stimulates a membrane-associated guanylate cyclase. Biochem J 1995; 311:45–47.PubMedGoogle Scholar
  17. 17.
    Barger, S.W., Mattson, M.P. Secreted form of the Alzheimer’s amyloid precursor protein induces neuroprotective κB-dependent transcription. Mol Brain Res 1996; 40:116–126.PubMedGoogle Scholar
  18. 18.
    Mattson, M.P., Barger, S.W., Furukawa, K., et al. Cellular signaling roles of TGFβ, TNF and βAPP in brain injury responses and Alzheimer’s disease. Brain Res — Brain Res Rev 1997; 23: 47–61PubMedGoogle Scholar
  19. 19.
    Barger, S.W., Harmon, A.D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997; 388:878–81.PubMedGoogle Scholar
  20. 20.
    Grimaldi, L.M., Casadei, V.M., Ferri, C., et al. Association of early-onset Alzheimer’s disease with an interleukin-1α gene polymorphism. Ann Neurol 2000; 47: 361–5.PubMedGoogle Scholar
  21. 21.
    Nicoli, J.A., Mrak, R.E., Graham,D.I., et al. Association of interleukin-1 gene polymorphisms with Alzheimer’s disease. Ann Neurol 2000; 47: 365–8.Google Scholar
  22. 22.
    Du, Y., Dode,l R.C., Eastwood, B.J., et al. Association of an interleukin la polymorphism with Alzheimer’s disease. Neurology 2000; 55: 480–3, 2000Google Scholar
  23. 23.
    Minster, R.L., DeKosky, S.T., Ganguli, M., Belle S, et al. Genetic association studies of interleukin-1 (IL-1A and IL-1B) and interleukin-1 receptor antagonist genes and the risk of Alzheimer’s disease. Ann Neurol 2000; 48: 817–9.PubMedGoogle Scholar
  24. 24.
    Rebeck, G.W. Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer’s disease. Neurosci Lett 2000; 293: 75–7.PubMedGoogle Scholar
  25. 25.
    Bertram, L., Blacker, D., Crystal, A., et al. Candidate genes showing no evidence for association or linkage with Alzheimer’s disease using family-based methodologies. Exp Gerontol 2000; 35: 1353–61, 2000Google Scholar
  26. 26.
    Collins, J.S., Perry, R.T., Watson Jr, B., et al. Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative. Am J Med Gen 2000; 96: 823–30.Google Scholar
  27. 27.
    McCusker, S.M., Curran, M.D., Dynan, K.B., et al. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor a and risk of Alzheimer’s disease and vascular dementia: a case-control study. Lancet 2001; 357: 436–9.PubMedGoogle Scholar
  28. 28.
    Luedecking, E.K., DeKosky, S.T., Mehdi, H., et al. Analysis of genetic polymorphisms in the transforming growth factor-βl gene and the risk of Alzheimer’s disease. Human Genet 2000; 106: 565–9.Google Scholar
  29. 29.
    Papassotiropoulos, A., Bagli, M., Jessen, F., et al. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer’s disease. Ann Neurol 1999; 45: 666–8.PubMedGoogle Scholar
  30. 30.
    Bhojak, T.J., DeKosky, S.T., Ganguli, M., et al. Genetic polymorphisms in the cathepsin D and interleukin-6 genes and the risk of Alzheimer’s disease. Neurosci Lett 2000; 288: 21–4.PubMedGoogle Scholar
  31. 31.
    Goldgaber, D., Harris, H.W., Hla, T., et al. Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 1989; 86: 7606–10.PubMedGoogle Scholar
  32. 32.
    Forloni, G., Demicheli, F., Giorgi, S., et al. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Brain Res Molec Brain Res 1992; 16: 128–34.Google Scholar
  33. 33.
    Buxbaum, J.D., Oishi, M., Chen, H.I., et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992; 89: 10075–10078.PubMedGoogle Scholar
  34. 34.
    Li, Y., Liu, L., Kang, J., et al. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 2000; 20: 149–155.PubMedGoogle Scholar
  35. 35.
    Lee, S.C., Liu, W., Dickson, D.W., et al. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL1β. J Immunol 1993; 150, 2659–67.PubMedGoogle Scholar
  36. 36.
    Sebire, G., Emilie, D., Wallon, C., Hery C, et al. In vitro production of IL6, IL1β, and tumor necrosis factor β by human embryonic microglial and neural cells. J Immunol 1993; 150: 1517–23.PubMedGoogle Scholar
  37. 37.
    Das, S., Potter, H. Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1. Neuron 1995; 14: 447–56.PubMedGoogle Scholar
  38. 38.
    Sheng, J.G., Ito, K., Skinner, R.D., et al. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force iti Alzheimer pathogenesis. Neurobiol Aging 1996; 17: 761–6.PubMedGoogle Scholar
  39. 39.
    Mrak R.E., Griffin, W.S.T. Interleukin-1 and the immunogenetics of Alzheimer disease. J Neuropathol Exp Neurol 2000; 59: 471–6.PubMedGoogle Scholar
  40. 40.
    Mrak, R.E., Griffin, W.S.T. Interleukin-1, neuroinflammation, and Alzheimer’s disease. Neurobiol Aging 2001; 22: 903–908.PubMedGoogle Scholar
  41. 41.
    Sheng, J.G., Mrak, R.E., Griffin, W.S.T. Microglial interleukin-lα expression in brain regions in Alzheimer’s disease: Correlation with neuritic plaque distribution. Neuropathol Appl Neurobiol 1996; 21: 290–301.Google Scholar
  42. 42.
    Sheng, J.G., Griffin, W.S.T., Royston, CM., et al. Distribution of IL-1-immunoreactive microglia in cerebral cortical layers: Implications for neuritic plaque formation in Alzheimer’s disease. Neuropathol Appl Neurobiol 1998; 24: 278–83.Google Scholar
  43. 43.
    Benzing, W.C., Wujek, J.R., Ward, E.K., et al. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging 1999; 20: 581–9.PubMedGoogle Scholar
  44. 44.
    Mehlhorn, G., Hollborn, M., Schliebs, R. Induction of cytokines in glial cells surrounding cortical β-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Develop Neurosci 2000; 18: 423–31.Google Scholar
  45. 45.
    Griffin, W.S.T., Sheng, J.G., Roberts, G.W., et al. Interleukin-1 expression in different plaque types in Alzheimer’s disease: significance in plaque evolution. J Neuropathol Exp Neurol 1995; 54: 276–281, 1995Google Scholar
  46. 46.
    Araujo, D.M., Cotman, C.W.. β-Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer’s disease. Brain Res 1992; 569:141–5.PubMedGoogle Scholar
  47. 47.
    Mackenzie IR, Hao C, Munoz DG. Role of microglia in senile plaque formation. Neurobiol Aging 16: 797–804, 1995PubMedGoogle Scholar
  48. 48.
    Allan, S.M., Parker, L.C., Collins, B., et al. Cortical cell death induced by IL-1 is mediated via actions in the hypothalamus of the rat. Proc Natl Acad Sci USA 2000; 97:5580–5.PubMedGoogle Scholar
  49. 49.
    Barger SW, Van Eldik LJ. S100B stimulates calcium fluxes in glial and neuronal cells. J Biol Chem 1992; 267:9689–9694.PubMedGoogle Scholar
  50. 50.
    Hu, J., Castets, F., Guevara, J.L., et al. S100B stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. J Biol Chem 1996; 271: 2543–7.PubMedGoogle Scholar
  51. 51.
    Casamenti, F., Prosperi, C., Scali, C., et al. Interleukin-lβ activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: implications for Alzheimer’s disease. Neurosci. 1999; 91: 831–42.Google Scholar
  52. 52.
    Sheng, J.G., Zhou, X.Q., Mrak, R.E., et al. Progressive neuronal injury associated with amyloid plaque formation in Alzheimer’s disease. J Neuropathol Exp Neurol 1998; 57: 714–7.PubMedGoogle Scholar
  53. 53.
    Sheng, J.G., Mrak, R.E., Griffin, W.S.T. Glial-neuronal interactions in Alzheimer disease: progressive association of IL-lα+ microglia and S100β+ astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol 1997; 56: 285–90.PubMedGoogle Scholar
  54. 54.
    Tarkowski, E., Blennow, K., Wallin, A., et al. Intracerebral production of tumor necrosis factor-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999; 19: 223–30.PubMedGoogle Scholar
  55. 55.
    Wolozin, B., Lesch, P., Lebovics, R., et al. A.E. Bennett Research Award 1993. Olfactory neuroblasts from Alzheimer donors: studies on APP processing and cell regulation. Biol Psychiatry 1993; 34: 824–38.PubMedGoogle Scholar
  56. 56.
    Sheng, J.G., Zhu, S.G., Jones, R.A., et al. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp Neurol 2000; 163: 388–391.PubMedGoogle Scholar
  57. 57.
    Griffin, W.S.T., Sheng, J.G., Royston, M.C., et al. Glial-neuronal interactions in Alzheimer’s disease: the potential role of a ‘cytokine cycle’ in disease progression. Brain Pathol 1998; 8: 65–72.PubMedGoogle Scholar
  58. 58.
    Mrak, R.E., Sheng, J.G., Griffin, W.S.T. Glial cytokines in Alzheimer’s disease: review and pathogenic implications. Hum Pathol 1995; 26: 816–823.PubMedGoogle Scholar
  59. 59.
    Donato, R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1450: 191–231, 1999PubMedGoogle Scholar
  60. 60.
    Shashoua, V.E., Hesse, G.W., Moore, B.W. Proteins of the brain extracellular fluid: evidence for release of S-100 protein. J Neurochem 1984; 42: 1536–1541.PubMedGoogle Scholar
  61. 61.
    Van Eldik, L.J., Zimmer, D.B. Secretion of S-100 from rat C6 glioma cells. Brain Res 1987; 436: 367–370.PubMedGoogle Scholar
  62. 62.
    Kligman, D., Marshak, D.R. Purification and characterization of a neurite extension factor from bovine brain. Proc Natl Acad Sci USA 1985; 82: 7136–7139.PubMedGoogle Scholar
  63. 63.
    Winningham-Major, F., Staecher, J.L., Barger, S.W., et al. Neurite extension and neuronal survival activities of recombinant S100β proteins that differ in the content and position of cysteine residues. J Cell Biol 1989; 109: 3036–71.Google Scholar
  64. 64.
    Barger, S.W., Van Eldik, L.J., Mattson, M.P. S100β protects hippocampal neurons from damage induced by glucose deprivation. Brain Res 1995; 677:167–70.PubMedGoogle Scholar
  65. 65.
    Selinfreund, R.H., Barger, S.W., Pledger, W.J., et al. Neurotrophic protein S100B stimulates glial cell proliferation. Proc Nat Acad Sci USA 1991; 88: 3554–3558.Google Scholar
  66. 66.
    Fano, G.. Mariggio, M.A.. Angelella, P., et al. The S-100 protein causes an increase of intracellular calcium and death of PC12 cells. Neurosci. 1993;53:919–25.Google Scholar
  67. 67.
    Mrak, R.E., Sheng, J.G., Griffin W.S.T. Correlation of astrocytic S100B expression with dystrophic neurites in amyloid plaques of Alzheimer’s disease. J Neuropathol Exp Neurol 1996; 55: 273–279.PubMedGoogle Scholar
  68. 68.
    Sheng, J.G., Mrak, R.E., Griffin, W.S.T. S100B protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques. J Neurosci Res 1994; 39: 398–404.Google Scholar
  69. 69.
    Marshak, D.R., Pesce, S.A., Stanley, L.C., et al. Increased S100 neurotrophic activity in Alzheimer disease temporal lobe. Neurobiol Aging 1992; 13: 1–7.PubMedGoogle Scholar
  70. 70.
    Mandybur, T.I., Chuirazzi, C.C. Astrocytes and the plaques of Alzheimer’s disease. Neurology 1990; 40: 635–639.PubMedGoogle Scholar
  71. 71.
    Van Eldik, L.J., Griffin, W.S.T. S100B expression in Alzheimer’s disease: Relation to neuropathology in brain regions. Biochim Biophys Acta 1994; 1223: 398–403.PubMedGoogle Scholar
  72. 72.
    Braak, H., Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239–259.PubMedGoogle Scholar
  73. 73.
    Mrak, R.E., Griffin, W.S.T. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease. Neurobiol Aging 2001; 22: 915–922.PubMedGoogle Scholar
  74. 74.
    Da Cunha, A., Jefferson, J.A., Jackson, R.W., et al. Glial cell-specific mechanisms of TGF-βl induction by IL-1 in cerebral cortex. J Neuroimmunol 1993; 42: 71–86.PubMedGoogle Scholar
  75. 75.
    Meda, L., Baron, P., Prat, E., et al. Pro-inflamatory profile of cytokine production by human monocytes and murine microglia stimulated with β-amyloid(25–35). J Neuroimmunol 1999; 93: 45–52.PubMedGoogle Scholar
  76. 76.
    Flanders, K.C., Lippa, C.F., Smith, T.W., et al. Altered expression of transforming growth factor-β in Alzheimer’s disease. Neurology 1995; 45: 1561–9.PubMedGoogle Scholar
  77. 77.
    Luterman, J.D., Haroutunian, V., Yemul, S., et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol 2000; 57: 1153–60.PubMedGoogle Scholar
  78. 78.
    Wyss-Coray, T., Masliah, E., Mallory, M., et al. Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer’s disease. Nature 1997; 389: 603–6.PubMedGoogle Scholar
  79. 79.
    Peress, N.S., Perillo, E. Differential expression of TGF-β 1, 2 and 3 isotypes in Alzheimer’s disease: a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. J Neuropathol Exp Neurol 1995; 54: 802–11.PubMedGoogle Scholar
  80. 80.
    Chao, C.C., Ala, T.A., Hu, S., et al. Serum cytokine levels in patients with Alzheimer’s disease. Clin Diagn Lab Immunol 1994; 1: 433–6.PubMedGoogle Scholar
  81. 81.
    Gray, C.W., Patel, A.J. Regulation of β-amyloid precursor protein isoform mRNAs by transforming growth factor-βl and interleukin-1β in astrocytes. Brain Res Molec Brain Res 1993; 19: 251–6.Google Scholar
  82. 82.
    Frautschy, S.A., Yang, F., Calderon, L., et al. Rodent models of Alzheimer’s disease: rat Aβ infusion approaches to amyloid deposits. Neurobiol Aging 1996; 17: 311–21.PubMedGoogle Scholar
  83. 83.
    Wyss-Coray, T., Lin, C., Sanan, D.A., et al. Chronic overproduction of transforming growth factor-βl by astrocytes promotes Alzheimer’s disease-like microvascular degeneration in transgenic mice. Am J Pathol 2000; 156: 139–50.PubMedGoogle Scholar
  84. 84.
    Wyss-Coray, T., Lin, C., von Euw, D., et al. Alzheimer’s disease-like cerebrovascular pathology in transforming growth factor-βl transgenic mice and functional metabolic correlates. Ann N Y Acad Sci 2000; 903: 317–23.PubMedGoogle Scholar
  85. 85.
    Wyss-Coray, T., Lin, C., Yan, F., et al. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nature Med 2001; 7: 612–8.PubMedGoogle Scholar
  86. 86.
    Li, Y., Barger, S.W., Liu, L., et al. S100B induction of the pro-inflammatory cytokine interleukin-6 in neurons: Implications for Alzheimer pathogenesis. J Neurochem 2000; 74: 143–50.PubMedGoogle Scholar
  87. 87.
    Del Bo, R., Angeretti, N., Lucca, E., et al. Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures. Neurosci Lett 1995; 188: 70–4.PubMedGoogle Scholar
  88. 88.
    Ringheim, G.E., Szczepanik, A.M., Petko, W., et al. Enhancement of β-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex. Brain Res Molec Brain Res 1998; 55: 35–44.Google Scholar
  89. 89.
    Kordula, T., Rydel, R.E., Brigham, E.F., et al. Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate. α1-antichymotrypsin expression in human cortical astrocytes. J Biol Chem 1998; 273: 4112–8.PubMedGoogle Scholar
  90. 90.
    Gitter, B.D., Cox, L.M., Rydel, R.E., et al. Amyloid β peptide potentiates cytokine secretion by interleukin-lβ-activated human astrocytoma cells. Proc Natl Acad Sci USA 1995; 92: 10738–41.PubMedGoogle Scholar
  91. 91.
    Strauss, S., Bauer, J., Ganter, U., et al. Detection of interleukin-6 an4 α2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer’s disease patients. Lab Invest 1992; 66: 223–30.PubMedGoogle Scholar
  92. 92.
    Huell, M., Strauss, S., Volk, B., et al. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer’s disease patients. Acta Neuropathol 1995; 89: 544–51.PubMedGoogle Scholar
  93. 93.
    Hull, M., Berger, M., Volk, B., et al. Occurrence of interleukin-6 in cortical plaques of Alzheimer’s disease patients may precede transformation of diffuse into neuritic plaques. Ann N Y Acad Sci 1996; 777: 205–12.PubMedGoogle Scholar
  94. 94.
    Thal, D.R., Schober, R., Birkenmeier, G. The subunits of α2-macroglobulin receptor/low density lipoprotein receptor-related protein, native and transformed α 2-macroglobulin and interleukin 6 in Alzheimer’s disease. Brain Res 1997; 777: 223–7.PubMedGoogle Scholar
  95. 95.
    Lanzrein, A.S., Johnston, C.M., Perry, V.H., et al. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-lβ, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-α, the soluble tumor necrosis factor receptors I and II, and α1-antichymotrypsin. Alzh Dis Assoc Dis 1998; 12: 215–27.Google Scholar
  96. 96.
    Wood, J.A., Wood, P.L., Ryan, R., et al. Cytokine indices in Alzheimer’s temporal cortex: no changes in mature IL-1β or IL-1RA but increases in the associated acute phase proteins IL-6, α2-macroglobulin and C-reactive protein. Brain Res 1993; 629: 245–52.PubMedGoogle Scholar
  97. 97.
    Blum-Degen, D., Muller, T., Kuhn, W., et al. Interleukin-lβ and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 1995; 202: 17–20.PubMedGoogle Scholar
  98. 98.
    Martinez, M., Fernandez-Vivancos, E., Frank, A., et al. Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer’s disease. Relationship with IL-6 concentrations. Brain Res 2000; 869: 216–9.PubMedGoogle Scholar
  99. 99.
    Marz, P., Heese, K., Hock, C., et al. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer’s disease patients. Neurosci Lett 1997; 239: 29–32.PubMedGoogle Scholar
  100. 100.
    Engelborghs, S., De Brabander, M., De Cree, J., et al. Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochem Int 1999; 34: 523–30.PubMedGoogle Scholar
  101. 101.
    Yamada, K., Kono, K., Umegaki, H., et al. Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia. Neurosci Lett 1995; 186: 219–21.PubMedGoogle Scholar
  102. 102.
    Dinarello, C.A. Pro-inflamatory cytokines. Chest 2000; 118: 503–508.PubMedGoogle Scholar
  103. 103.
    Benveniste EN, Benos DJ. TNF-α- and IFN-γ-mediated signal transduction pathways: effects on glial cell gene expression and function. FASEB J 1995; 9: 15577–1584.Google Scholar
  104. 104.
    Meda, L., Cassatella, M.A., Szendrei, G.I., et al. Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 1995; 374: 647–50.PubMedGoogle Scholar
  105. 105.
    Viviani, B., Corsini, E., Galli, C.L., et al. Dying neural cells activate glia through the release of a protease product. GLIA 2000; 32: 84–90.PubMedGoogle Scholar
  106. 106.
    Blasko, I., Marx, F., Steiner, E., et al. TNFα plus IFNγ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. FASEB J 1999; 13: 63–8.PubMedGoogle Scholar
  107. 107.
    Mattson, M.P., Barger, S.W., Cheng, B., et al. β-Amyloid precursor protein metabolites and loss of neuronal calcium homeostasis in Alzheimer’s disease. Trends Neurosci 1993; 16: 409–415.PubMedGoogle Scholar
  108. 108.
    Murphy, G.M., Jr, Yang, L., Cordell, B.. Macrophage colony-stimulating factor augments β-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells. J Biol Chem 1998; 273: 20967–71.PubMedGoogle Scholar
  109. 109.
    Murphy, G.M., Jr, Zhao, F., Yang, L., et al. Expression of macrophage colony-stimulating factor receptor is increased in the AβPP(V717F) transgenic mouse model of Alzheimer’s disease. Am J Pathol 2000; 157: 895–904.PubMedGoogle Scholar
  110. 110.
    Mennicken, F., Maki, R., de Souza, E.B., et al. Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. Trends Pharmacol Sci 1999; 20: 73–8.PubMedGoogle Scholar
  111. 111.
    Xia, M.Q., Hyman,, B.T. Chemokines/chemokine receptors in the central nervous system and Alzheimer’s disease. J Neuro Virol 1999; 5: 32–41.Google Scholar
  112. 112.
    Fiala, M., Zhang, L., Gan, X., et al. Amyloid-β induces chemokine secretion and monocyte migration across a human blood--brain barrier model. Molec Med 1998; 4: 480–9.Google Scholar
  113. 113.
    Szczepanik, A.M., Funes, S., Petko, W., et al. IL-4, IL-10 and IL-13 modulate Aβ(l--42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J Neuroimmunol 2001; 113: 49–62PubMedGoogle Scholar
  114. 114.
    Johnstone, M., Gearing, A.J., Miller, K.M.. A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced. J Neuroimmunol 1999; 93: 182–93.PubMedGoogle Scholar
  115. 115.
    Lahiri, D.K., Nail, C. Promoter activity of the gene encoding the β-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Brain Res Molec Brain Res 1995; 32: 233–40.Google Scholar
  116. 116.
    Rossi, F., Bianchini E. Synergistic induction of nitric oxide by β-amyloid and cytokines in astrocytes. Biochem Biophys Res Commun 1996; 225: 474–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • Robert E. Mrak
    • 1
  1. 1.University of Arkansas for Medical SciencesLittle RockUSA

Personalised recommendations